Carmat has announced the first implantation of its bioprosthetic artificial heart, Aeson, in the USA within the framework of an Early Feasibility Study (EFS).

Carmat has announced the first implantation of its bioprosthetic artificial heart, Aeson, in the USA within the framework of an Early Feasibility Study (EFS).

atHeart Medical has announced the successful treatment of the first five patients in its ASCENT ASD US Investigational Device Exemption (IDE) pivotal trial. This study, the company’s first in the USA, will evaluate the safety and efficacy of the reSept atrial septal defect (ASD) occluder.

Global action is needed to improve clinician wellbeing, according to four leading cardiovascular health organisations, who have issued a joint paper calling for an increased recognition of the impact of clinician burnout, particularly due to the COVID-19 pandemic. The comments have come jointly from the American College of Cardiology (ACC), the American Heart Association (AHA), the European Society of Cardiology (ESC) and the World Heart Federation (WHF).

The American Heart Association (AHA) has published a scientific statement challenging “traditionally held” cath lab practices, and instead offering evidence-based recommendations where these could be reconsidered.

Sinomed has announced a partnership with the National University of Ireland Galway (NUI Galway, Galway, Ireland) to conduct a clinical trial for a new assessment method for stenting. The trial will employ the newly patented, HT Supreme healing-targeted drug-eluting stent (DES).

Assessment of patients by both interventional cardiologists and cardiac surgeons prior to transcatheter aortic valve intervention (TAVI)—known as the heart team approach—appears to be declining, particularly in centres with more mature TAVI programmes. This is according to a study of temporal trends of heart team utilisation in TAVI referrals and treatment allocation in Ontario, Canada from 2012–2019, findings from which were published online in the Journal of the American Heart Association (JAHA).  

Clinical practice guidance released today outline recommendations for reducing blood loss during cardiothoracic surgery and improving patient outcomes. The document, a multidisciplinary collaboration among The Society of Thoracic Surgeons (STS), the Society of Cardiovascular Anesthesiologists (SCA), the American Society of ExtraCorporeal Technology (AmSECT), and the Society for the Advancement of Patient Blood Management (SABM), is available online in The Annals of Thoracic Surgery and two other journals.

Royal Philips has announced the first procedure using its real-time 3D intracardiac echocardiography (ICE) catheter. The left atrial appendage occlusion (LAAO) procedure was carried out by Mohamad Adnan Alkhouli (Mayo Clinic, Minnesota, USA).

Abbott has today announced that its XIENCE family of stents has received US Food and Drug Administration (FDA) approval for one-month (as short as 28 days) dual antiplatelet therapy (DAPT) labelling for high bleeding risk (HBR) patients in the USA. This follows the receipt of CE mark in Europe for shorter duration DAPT in April 2021.

Electroducer has announced that it has raised €3 million (US$3.65M) from private investors and French public stakeholders which will be used for marketing its new technology—the Electroducer Sleeve. The device is based on a technique called direct wire pacing (DWP) and is used to treat heart valve disease.